<DOC>
	<DOCNO>NCT01531751</DOCNO>
	<brief_summary>The aim study assess survival patient advance cardiac AL amyloidosis treat high cut-off hemodialysis ( HCO-HD ) combine chemotherapy .</brief_summary>
	<brief_title>High Cut-off Hemodialysis Patients With Advanced Cardiac AL Amyloidosis End Stage Renal Disease</brief_title>
	<detailed_description>This single-center phase II open label trial . Subjects advance cardiac AL amyloidosis end-stage renal disease undergo HCO-HD receiving chemotherapy plasma cell dyscrasia accord current standard care . After give write informed consent , patient evaluate eligibility . Briefly , subject biopsy-proven diagnosis AL amyloidosis cardiac stage 3 base NT-proBNP ( &gt; 332 ng/L ) cTnI ( &gt; 100 ng/L ) whose estimate glomerular filtration rate ( eGFR ) &lt; 15 mL/min per 1.73 m2 eligible study . Patients non-AL ( e.g . familial senile ) amyloidosis exclude , well subject le 100 mg/L circulate amyloidogenic FLC . Sixteen patient enrol . The study include 3 period : screening , treatment follow end-of-treatment evaluation follow-up . During dialysis patient undergo first cycle chemotherapy accord current standard care subject advance cardiac AL amyloidosis . Measurements FLC cardiac biomarkers do dialysis session . High cutoff HD continue first chemotherapy cycle . After first cycle end-of-treatment evaluation take place . Follow-up evaluation perform end subsequent chemotherapy cycle every 2 month chemotherapy discontinuation 1 year disease progression occur .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Diagnosis AL amyloidosis . Age ≥ 18 year . Evidence monoclonal light chain serum and/or urine positive immunofixation abnormal FLC κ/λ ratio . Evidence cardiac involvement echocardiography ( mean leave ventricular wall thickness &gt; 12 mm absence cause ) . Cardiac stage III ( NTproBNP &gt; 332 ng/L cTnI &gt; 100 ng/L ) . Estimated GFR &lt; 15 mL/min per 1.73 m2 require dialysis . NYHA class III IV . Initiation chemotherapy AL amyloidosis schedule day 3 day 8 first HCOHD session . NonAL ( e.g . familial , senile ) amyloidosis . Concomitant nonamyloid relate clinically significant cardiac disease . Involved ( amyloidogenic ) FLC &lt; 100 mg/L . Inability undergo chemotherapy AL amyloidosis . Uncontrolled infection . Inability give inform consent . Previous ongoing psychiatric illness ( exclude reactive depression ) . Pregnant nursing woman .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>HCO-HD</keyword>
	<keyword>survival</keyword>
	<keyword>cardiac biomarkers</keyword>
	<keyword>AL amyloidosis</keyword>
	<keyword>Light Chain Amyloidosis</keyword>
</DOC>